Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Lifetime prevalence 2-3%. Chronic and debilitating. Up to 40-60% of patients do not respond adequately to first-line SSRI therapy.
ERP (Exposure and Response Prevention), high-dose SSRIs (often 2-3x depression doses), clomipramine. Augmentation with antipsychotics. DBS for severe refractory cases.
Psilocybin targets the serotonin system, which is centrally involved in OCD pathology. By acutely stimulating 5-HT2A receptors and disrupting cortico-striato-thalamo-cortical circuits, psilocybin may 'reset' the repetitive thought loops that characterize OCD.
Moreno et al. (2006): All 9 subjects showed marked decreases in OCD symptoms with psilocybin (Y-BOCS reductions of 23-100%). Onset within hours.